Please provide your email address to receive an email when new articles are posted on . The study examined efficacy of subcutaneous vs. oral administration of carbidopa/levodopa. Subcutaneous infusion ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Foscarbidopa and foslevodopa are pro-drugs for carbidopa and levodopa, which are standard-of-care Parkinson's treatments. The new treatment, formerly know as ABBV-951, is the first subcutaneous ...
The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for ...
A 24-hour continuous subcutaneous infusion of foslevodopa/foscarbidopa improved Parkinson's disease (PD) motor symptoms during all waking hours for patients with ...
NORTH CHICAGO, Ill., Oct. 28, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that continuous 24 hours/day subcutaneous infusion of ABBV-951 (foslevodopa ...
The Department of Health and the Welsh Assembly Government have asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a multiple technology appraisal of ...
The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...
Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children. Units for reporting HbA1c have changed from % to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback